BioWorld

July 2, 2007

View Archived Issues

Genmab 'Celebrating' Return Of Worldwide HuMax-CD4 Rights

Genmab A/S said it is moving full steam ahead with its late-stage HuMax-CD4 compound in cutaneous T-cell lymphoma after regaining full rights to the drug from partner Merck Serono SA. (BioWorld Today) Read More

Cytokinetics' Ispinesib Mixed In Phase II Cancer Outcomes

Read More

Cutting Asymmetric DNA Is Basis For Potential HIV Cure

Read More

Peregrine Brings In $22.5M To Support Cancer, HCV Studies

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More